Cargando…
Why clinical trial outcomes fail to translate into benefits for patients
Clinical research should ultimately improve patient care. For this to be possible, trials must evaluate outcomes that genuinely reflect real-world settings and concerns. However, many trials continue to measure and report outcomes that fall short of this clear requirement. We highlight problems with...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5348914/ https://www.ncbi.nlm.nih.gov/pubmed/28288676 http://dx.doi.org/10.1186/s13063-017-1870-2 |
_version_ | 1782514356877000704 |
---|---|
author | Heneghan, Carl Goldacre, Ben Mahtani, Kamal R. |
author_facet | Heneghan, Carl Goldacre, Ben Mahtani, Kamal R. |
author_sort | Heneghan, Carl |
collection | PubMed |
description | Clinical research should ultimately improve patient care. For this to be possible, trials must evaluate outcomes that genuinely reflect real-world settings and concerns. However, many trials continue to measure and report outcomes that fall short of this clear requirement. We highlight problems with trial outcomes that make evidence difficult or impossible to interpret and that undermine the translation of research into practice and policy. These complex issues include the use of surrogate, composite and subjective endpoints; a failure to take account of patients’ perspectives when designing research outcomes; publication and other outcome reporting biases, including the under-reporting of adverse events; the reporting of relative measures at the expense of more informative absolute outcomes; misleading reporting; multiplicity of outcomes; and a lack of core outcome sets. Trial outcomes can be developed with patients in mind, however, and can be reported completely, transparently and competently. Clinicians, patients, researchers and those who pay for health services are entitled to demand reliable evidence demonstrating whether interventions improve patient-relevant clinical outcomes. |
format | Online Article Text |
id | pubmed-5348914 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-53489142017-03-14 Why clinical trial outcomes fail to translate into benefits for patients Heneghan, Carl Goldacre, Ben Mahtani, Kamal R. Trials Commentary Clinical research should ultimately improve patient care. For this to be possible, trials must evaluate outcomes that genuinely reflect real-world settings and concerns. However, many trials continue to measure and report outcomes that fall short of this clear requirement. We highlight problems with trial outcomes that make evidence difficult or impossible to interpret and that undermine the translation of research into practice and policy. These complex issues include the use of surrogate, composite and subjective endpoints; a failure to take account of patients’ perspectives when designing research outcomes; publication and other outcome reporting biases, including the under-reporting of adverse events; the reporting of relative measures at the expense of more informative absolute outcomes; misleading reporting; multiplicity of outcomes; and a lack of core outcome sets. Trial outcomes can be developed with patients in mind, however, and can be reported completely, transparently and competently. Clinicians, patients, researchers and those who pay for health services are entitled to demand reliable evidence demonstrating whether interventions improve patient-relevant clinical outcomes. BioMed Central 2017-03-14 /pmc/articles/PMC5348914/ /pubmed/28288676 http://dx.doi.org/10.1186/s13063-017-1870-2 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Commentary Heneghan, Carl Goldacre, Ben Mahtani, Kamal R. Why clinical trial outcomes fail to translate into benefits for patients |
title | Why clinical trial outcomes fail to translate into benefits for patients |
title_full | Why clinical trial outcomes fail to translate into benefits for patients |
title_fullStr | Why clinical trial outcomes fail to translate into benefits for patients |
title_full_unstemmed | Why clinical trial outcomes fail to translate into benefits for patients |
title_short | Why clinical trial outcomes fail to translate into benefits for patients |
title_sort | why clinical trial outcomes fail to translate into benefits for patients |
topic | Commentary |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5348914/ https://www.ncbi.nlm.nih.gov/pubmed/28288676 http://dx.doi.org/10.1186/s13063-017-1870-2 |
work_keys_str_mv | AT heneghancarl whyclinicaltrialoutcomesfailtotranslateintobenefitsforpatients AT goldacreben whyclinicaltrialoutcomesfailtotranslateintobenefitsforpatients AT mahtanikamalr whyclinicaltrialoutcomesfailtotranslateintobenefitsforpatients |